ChangXin Memory Technology (CXMT) listed on the STAR Market at 8.66 yuan per share, commanding a market cap of 579 billion yuan. That is roughly $80 billion. For context, Samsung's DRAM division—which holds 40% of the global market and operates at 90%+ yield on 1β nm—trades at a P/B of 2x. CXMT's P/B is 8x. The offering raised 57.9 billion yuan, enough to buy a fleet of ASML EUV machines. But CXMT cannot buy those machines. It is on the U.S. Entity List.
The narrative is simple: China needs its own DRAM, CXMT is the only player, and the government backs it. But narratives do not survive a stress test. I have spent 24 years dissecting technical systems—from Ethereum's gas price anomalies in 2017 to Compound's interest rate accumulator flaws in 2020. Every time a protocol raises capital on a story instead of data, the rot is hidden but not erased. CXMT's IPO is no different.
Context: The DRAM Dilemma CXMT is the only Chinese company mass-producing DRAM at scale. Its current node is 17nm/19nm, yielding 80-85% on mature DDR4/LPDDR4. The industry leaders—Samsung, SK Hynix, Micron—are already at 1β nm (≈12nm) with yields above 90%. That is a gap of 1.5 to 2 nodes, or roughly 3-4 years in manufacturing time. CXMT's roadmap targets 1β nm by 2027-2028, but that timeline assumes unrestricted access to ASML DUV immersion lithography. Currently, its DUV tools are under export license limbo. The only path forward is domestic alternatives (SMEE), which trail by at least a generation.
Core: The Systematic Teardown Let’s start with technology. DRAM is not software—you cannot fork a codebase and iterate. Every nanometer shrink requires precise etch, deposition, and lithography tools. ASML’s NXT:1980i series is the baseline for 17nm. For 1β nm, you need the NXT:2000i or better. CXMT cannot buy new ones. It relies on hoarded inventory and second-hand tools. In my 2022 Terra-Luna consensus analysis, I traced the exact block height where liveness failed due to validator pre-commit delays. Here, the failure point is predictable: a U.S. ban on maintenance and spare parts would freeze CXMT’s fab within months. The Entity List designation is not a badge of honor; it is a throttle.
Next, supply chain. CXMT imports 100% of its lithography machines, 80-90% of its etch and deposition tools, and over 90% of its high-end photoresist. The domestic substitution rate hovers at 15-20%. The IPO prospectus likely highlights agreements with Huawei and ByteDance, but those customers cannot fix a broken stepper. I once audited a Bored Ape Yacht Club contract where the metadata relied on a centralized IPFS gateway—a single point of failure. CXMT’s fab is that gateway, except the DNS is controlled by the Bureau of Industry and Security.
Third, valuation. 579 billion yuan implies a P/S of 10-15x. Samsung’s DRAM division trades at 2x P/S. Even if CXMT captures 15-20% of China’s DRAM market (from 3% now), it would need to grow revenue 5x just to justify the current multiple. But margin is the rub. CXMT’s gross margin is 5-15% due to low yield and high depreciation. Samsung in a downturn maintains 20%+. The depreciation burden alone (30%+ of revenue) will suppress margins for years. At its current run rate, CXMT is likely destroying value (ROIC < WACC). The IPO is a lifeline, not a sign of health.
Contrarian: What the Bulls Got Right Not everything is rot. The domestic demand for DRAM is real. China consumes about 30% of global DRAM, and with U.S. sanctions limiting CXMT’s overseas sales, the local market is a captive audience. Huawei, for example, cannot fully rely on Samsung or Micron for LPDDR4/5 due to supply chain decoupling. That creates a price premium for CXMT’s products. Also, the Chinese government has deep pockets. The IPO itself is underwritten by China International Capital Corporation (CICC), a state-backed entity. If CXMT’s stock slumps, state funds can prop it up. In a bear market for tech IPOs, this stability mechanism is non-trivial.
But here is the catch: a stable stock price does not mean a stable business. I analyzed BlackRock’s iShares ETF smart contract in 2024 and found that the multi-sig lacked hardware redundancy for fail-over. CXMT’s capital structure is similarly fragile—the IPO covers existing loans but does not eliminate the operational risk. The bulls assume that domestic equipment makers will fill the gap within 5 years, but my experience in DeFi stress-testing says otherwise. Compound Finance’s interest rate model looked robust until I simulated a 60% price drop in ETH collateral. CXMT’s roadmap assumes linear progress; in reality, equipment development is nonlinear and often regresses under export controls.
Takeaway: Accountability Call CXMT’s IPO is a strategic capital operation, not a technical milestone. The market is pricing in a narrative of self-sufficiency that the hardware cannot yet support. Investors need to track two signals: (1) the delivery of new DUV tools (or domestic equivalents) and (2) the yield at 1β nm pilot runs. Until those numbers are verifiable, the 579 billion yuan is a bet on political resolve, not on physics. A pixelated image cannot hide a structural rot. Verify the hash, ignore the narrative.
Volatility is just data waiting to be dissected.',
